Dercum's disease: a rare and underdiagnosed disease

RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients

“…Based on in vitro and in vivo preclinical studies, the putative mechanism of action of RZL-012 seems to operate through induction of significant fat cell necrosis after a single injection with transient side effects, mostly at the injected area. An open label Phase 2a trial in 6 Dercum's disease patients 1,2 was undertaken to confirm initial safety and efficacy. Patients were dosed once by injecting the compound into painful lipomas.…”